Development of stable and regulated gene expression system for gene therapy
开发用于基因治疗的稳定且受调控的基因表达系统
基本信息
- 批准号:12672145
- 负责人:
- 金额:$ 2.18万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2000
- 资助国家:日本
- 起止时间:2000 至 2001
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In basic genetic research, control oftransgene expression in mammalian cells should be desirable forgene therapyand the studyofgene function. Permanentand higher levels of gene expression should be also preferable. The expression levels of the introduced gene depend mostly on the strength oftranscriptional regulatory elements and the transduction efficiency of the gene transfer vector.In this study, we investigated the effective combination of commonly-used regulatory elements, such as the promoter/enhancer, intron, and polyadenylation signal (P(A)) sequence by constructing a series of plasmids and recombinant adenovirus vectors that differed only in the particular sequence element being evaluated. Of the several promoter/enhancers that were tested, hybrid CA promoter/enhancer containing human cytomegalovirus immediate-early 1 gene (CMV) enhancer and chicken β-actin promoterwith the β-actin intron sequence, and the improved CMV promoter/enhancer containing the largest intron of CMV(int … More ron A) produced the highest levels of expression both in vitro and in vivo. P(A)sequences were found to have significant effects on transgene expression. These comparative analyses could provide a systematic reference for the development of vector construction for gene therapy, vaccine development, and gene transfer experiments.Next, we examined the stable gene expression using the plasmids containing the components derived from adeno-associated virus (AAV). We examined the efficiency of colony formation of the neomycin resistant cells which were transfected with the plasmid containing neomycin resistant gene franked with AAVITR (inverted terminal repeat). Number of colony of neomycin resistant cells transfected with the plasmid with AAVITR and Rep78(AAVderived proteinj-expressing plasmid was much higher than that with the plasmid without AAVITRand Rep78expressing plasmid, suggesting that Rep78 protein assisted the integration of the foreing gene intothe host genome. We are now applying this techiniqes intothe integration of the genomic foreign DNA into the host genome. This system using genomic DNA could get stable and regulated gene expression. Less
在基础遗传学研究中,控制转基因在哺乳动物细胞中的表达是基因治疗和基因功能研究的需要。永久和更高水平的基因表达也应该是更可取的。导入基因的表达水平主要取决于转录调控元件的强度和基因转移载体的转导效率。在本研究中,我们通过构建一系列仅在特定序列元件上存在差异的质粒和重组腺病毒载体,研究了启动子/增强子、内含子和多聚腺苷信号(P(A))序列等常用调控元件的有效组合。在测试的几个启动子/增强子中,含有人巨细胞病毒即刻早期1基因(CMV)增强子和鸡β-肌动蛋白启动子的杂交CA启动子/增强子带有β-肌动蛋白内含子序列,以及含有CMV最大内含子(INT…)的改进的CMV启动子/增强子更多的RON A)在体外和体内均产生最高水平的表达。P(A)序列对转基因表达有显著影响。这些比较分析可以为基因治疗、疫苗开发和基因转移实验的载体构建提供系统的参考。接下来,我们使用含腺相关病毒(AAV)组件的质粒检测了稳定的基因表达。我们检测了以AAVITR(反向末端重复序列)标记的新霉素抗性基因表达载体对新霉素耐药细胞集落形成的影响。含AAVITR和Rep78(AAV衍生蛋白)表达载体的新霉素耐药细胞克隆数明显高于不含AAVITR和Rep78表达载体的细胞克隆数,提示Rep78蛋白有助于外源基因整合到宿主基因组中。我们现在正在将这项技术应用于将基因组中的外源DNA整合到宿主基因组中。该系统利用基因组DNA可以获得稳定的、可调控的基因表达。较少
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Xu Z.L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., Hayakawa T: "Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector"J. Control. Rel.. (in press).
Xu Z.L.,Mizuguchi H.,Ishii-Watabe A.,Uchida E.,Mayumi T.,Hayakawa T:“腺病毒载体转基因表达转录调控元件的强度评估”J.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.Mizuguchi, T.Hayakawa: "Characteristics of adenovirus-mediated tetracycline controllable expression system"Biochim. Biophys. Acta. 1568. 21-29 (2001)
H.Mizuguchi、T.Hayakawa:“腺病毒介导的四环素可控表达系统的特征”Biochim。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.Mizuguchi, T.Hayakawa: "Characteristics of adenovirus-mediated tetracycline controllable expression system"Biochim. Biophys. Acda. 1568. 21-29 (2001)
H.Mizuguchi、T.Hayakawa:“腺病毒介导的四环素可控表达系统的特征”Biochim。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Xu Z.L et al: "Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector"J. Control. Rel. (in Press).
Xu Z.L等:“腺病毒载体转基因表达转录调控元件的强度评估”J.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Mizuguchi H. et al: "Long-Term replication of Epstein-Barr virus-derived episomal vectors in the rodent cells"FEBS Letter. 472. 173-178 (2000)
Mizuguchi H.等人:“Epstein-Barr病毒衍生的附加型载体在啮齿动物细胞中的长期复制”FEBS Letter。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAYAKAWA Takao其他文献
HAYAKAWA Takao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 2.18万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 2.18万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Young Scientists (B)